Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: A pilot study

Journal of Pediatric and Adolescent Gynecology

Volumn 27, Issue 3, 2014, Pages 161-165

  Tartagni, Mario V ^a   Alrasheed, Hala ^a   Damiani, Gianluca R ^b   Montagnani, Monica ^c   De Salvia, Maria A ^c   De Pergola, Giovanni ^c   Tartagni, Massimo ^c   Loverro, Giuseppe ^c  

^a Medical Faculty   (Slovakia)

^b Hospital of Sondrio   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Adolescents; Finasteride; Hirsutism; Polycystic ovarian disease

Indexed keywords

ANDROSTENEDIOL; FINASTERIDE; GLUCURONIDE; PLACEBO; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIRSUTISM; HUMAN; LOW DRUG DOSE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; PATIENT SATISFACTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

5-ALPHA REDUCTASE INHIBITORS; ADOLESCENT; ANDROSTENEDIOL; DIHYDROTESTOSTERONE; FEMALE; FINASTERIDE; GLUCURONIDES; HIRSUTISM; HUMANS; PATIENT SATISFACTION; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84899918240     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2013.09.010     Document Type: Article

References (39)

1. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21:1440.
2. Loriaux D.L. An approach to the patient with hirsutism. J Clin Endocrinol Metab 2012, 97:2957.
3. Erkkola R., Ruutiainen K. Hirsutism: definitions and etiology. Ann Med 1990, 22:99.
4. Merino P.M., Codner E., Cassorla F. A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. Arq Bras Endocrinol Metabol 2011, 55:590.
5. Kuttenn F., Mowszowicz I., Schaison G., et al. Androgen production and skin metabolism in hirsutism. J Endocrinol 1977, 75:83.
6. Lobo R.A., Goebelsmann U., Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 1983, 57:393.
7. Sultan C., Medlej R., Chevalier C., et al. Management of hyperandrogenism in adolescent girls. Horm Res 1991, 36:160.
8. Stiles A.R., Russell D.W. SRD5A3: A surprising role in glycosylation. Cell 2010, 142:196.
9. Russell D.W., Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25.
10. Levy M.A., Brandt M., Sheedy K.M., et al. Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes. J Steroid Biochem Mol Biol 1995, 52:307.
11. Azzouni F., Godoy A., Li Y., et al. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012, 2012:530121.
12. Serafini P., Ablan F., Lobo R.A. 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985, 60:349.
13. Bumbuliene Z., Alisauskas J. Evaluation and treatment of adolescent girls with hirsutism. Ginekol Pol 2009, 80:374. [Article in Polish].
14. Wagner R.F. Physical methods for the management of hirsutism. Cutis 1990, 45:319.
15. La Marca A., Artensio A.C., Stabile G., et al. Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol 2005, 121:3.
16. Ibáñez L., Diaz M., Sebastiani G., et al. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab 2011, 96:3361.
17. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003, 101(5 Pt 1):995.
18. Paulson R.J., Serafini P.C., Catalino J.A., et al. Measurements of 3 alpha,17 beta-androstanediol glucuronide in serum and urine and the correlation with skin 5 alpha-reductase activity. Fertil Steril 1986, 46:222.
19. Rittmaster R.S. Finasteride. N Engl J Med 1994, 330:120.
20. Andersson S., Berman D.M., Jenkins E.P., et al. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354(6349):159.
21. Aggarwal S., Thareja S., Verma A., et al. An overview on 5alpha-reductase inhibitors. Steroids 2010, 75:109.
22. Girard J., Baumann J.B., Buhler U., et al. Cyproteroneacetate and ACTH adrenal function. J Clin Endocrinol Metab 1978, 47:581.
23. Bayram F., Muderris I.I., Guven M., et al. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol 2002, 147:467.
24. Tartagni M., Schonauer L.M., De Salvia M.A., et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2000, 73:718.
25. Tartagni M., Schonauer M.M., Cicinelli E., et al. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril 2004, 82:752.
26. Castello R., Tosi F., Perrone F., et al. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996, 66:734.
27. Lakryc E.M., Motta E.L., Soares J.M., et al. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol 2003, 17:57.
28. Venturoli S., Marescalchi O., Colombo F.M., et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999, 84:1304.
29. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183.
30. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
31. Moghetti P., Tosi F., Tosti A., et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000, 85:89.
32. Falsetti L., Gambera A., Platto C., et al. Management of hirsutism. Am J Clin Dermatol 2000, 1:89.
33. Bachelot A., Chabbert-Buffet N., Salenave S., et al. Anti-androgen treatments. Ann Endocrinol (Paris) 2010, 71:19.
34. Paparodis R., Dunaif A. The hirsute woman: challenges in evaluation and management. Endocr Pract 2011, 17:807.
35. Faloia E., Filipponi S., Mancini V., et al. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest 1998, 21:694.
36. Fruzzetti F., Bersi C., Parrini D., et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999, 71:445.
37. Lumachi F., Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003, 79:942.
38. Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996, 30:16.
39. Gormley G.J., Stoner E., Rittmaster R.S., et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990, 70:1136.